Algernon Pharmaceuticals finding new uses for safe, older drugs

Algernon Pharmaceuticals Inc (OTCMKTS:BTHCF) CEO Christoper Moreau sat down with Proactive’s Steve Darling at the 12th annual LD Micro Conference in Bel Air, California. The Vancouver, British Columbia-based clinical stage pharmaceutical development company is advancing its lead compounds for non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease and idiopathic pulmonary fibrosis.